1-20 of 25
Jordi Rodon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Mohamed A. Gouda, Amrit Gonugunta, Ecaterina E. Dumbrava, Timothy A. Yap, Jordi Rodon, Sarina A. Piha-Paul, Paula R. Pohlmann, Senthil Damodaran, Rashmi Murthy, Vicente Valero, Jason A. Mouabbi, Debasish Tripathy, Aysegul A. Sahin, Hui Chen, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF7.
https://doi.org/10.1158/1078-0432.CCR-24-3468
Published: 27 February 2025
View article titled, Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer
Open the PDF for Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer

Timothy P. DiPeri, Kurt W. Evans, Stephen Scott, Xiaofeng Zheng, Kaushik Varadarajan, Lawrence N. Kwong, Michael Kahle, Hop S. Tran Cao, Ching-Wei Tzeng, Thuy Vu, Sunhee Kim, Fei Su, Maria Gabriela Raso, Yasmeen Rizvi, Ming Zhao, Huamin Wang, Sunyoung S. Lee, Timothy A. Yap, Jordi Rodon, Milind Javle, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2): 387–402.
https://doi.org/10.1158/1078-0432.CCR-24-1233
Published: 17 January 2025
View article titled, Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer
Open the PDF for Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B011: Phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2 (PRECISION I)

Debra L. Richardson, Gopa Iyer, Li Ding, Anita N. Schmid, Willis Navarro, David Kwiatkowski, Jordi Rodon Ahnert
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (5_Supplement): B011.
https://doi.org/10.1158/1557-3265.ENDO24-B011
Published: 01 March 2024
View article titled, Abstract B011: Phase 2, multicenter, open-label basket trial of <em>nab</em>-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in <em>TSC1</em> and <em>TSC2</em> (PRECISION I)
Journal Articles

Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers

Tin-Yun Tang, Federico Nichetti, Ben Kaplan, Sara Lonardi, Filippo Pietrantonio, Lisa Salvatore, Caterina Vivaldi, Lorenza Rimassa, Filippo de Braud, Mario Domenico Rizzato, Dean Pavlick, Randy Chu, Anaemy Danner De Armas, Radwa Sharaf, Ethan Sokol, Jordi Rodon Ahnert, Jeffrey S. Ross, Milind Javle, Monica Niger
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4853–4862.
https://doi.org/10.1158/1078-0432.CCR-23-1926
Published: 01 December 2023
View article titled, Comparative Genomic Analysis and Clinical Outcomes of <em>BRAF</em>-mutated Advanced Biliary Tract Cancers
Open the PDF for Comparative Genomic Analysis and Clinical Outcomes of <em>BRAF</em>-mutated Advanced Biliary Tract Cancers in another window
Includes: Supplementary data
Journal Articles

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes

Ryan A. Denu, Richard K. Yang, Alexander J. Lazar, Shalin S. Patel, Valerae O. Lewis, Jason Roszik, J. Andrew Livingston, Wei-Lien Wang, Kenna R. Shaw, Ravin Ratan, Maria A. Zarzour, Justin Bird, Shaan Raza, Kadir C. Akdemir, Jordi Rodon Ahnert, Vivek Subbiah, Shreyaskumar Patel, Anthony P. Conley
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4844–4852.
https://doi.org/10.1158/1078-0432.CCR-23-1703
Published: 01 December 2023
View article titled, Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals <em>TP53</em> Mutation to Be Associated with Worse Outcomes
Open the PDF for Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals <em>TP53</em> Mutation to Be Associated with Worse Outcomes in another window
Includes: Supplementary data
Journal Articles

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Roberto Carmagnani Pestana, Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing, Cynthia E. Herzog, Siqing Fu, Sarina A. Piha-Paul, Jordi Rodon, Timothy A. Yap, Daniel D. Karp, Apostolia M. Tsimberidou, Shubham Pant, Maria A. Zarzour, Ravin Ratan, Vinod Ravi, Robert S. Benjamin, Alexander J. Lazar, Wei-Lien Wang, Najat Daw, Jonathan B. Gill, Douglas J. Harrison, Valerae O. Lewis, Christina L. Roland, Shreyaskumar R. Patel, J. Andrew Livingston, Neeta Somaiah, Joseph A. Ludwig, Anthony P. Conley, Nelson Hamerschlak, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1708–1718.
https://doi.org/10.1158/1078-0432.CCR-22-3629
Published: 01 May 2023
View article titled, Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Open the PDF for Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101) in another window
Includes: Supplementary data
Journal Articles

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Justin T. Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu, Sarina Piha-Paul, Timothy A. Yap, Daniel Karp, Jordi Rodon, Andy Livingston, Maria Alejandra Zarzour, Vinod Ravi, Shreyaskumar Patel, Robert S. Benjamin, Joseph Ludwig, Cynthia Herzog, Ravin Ratan, Neeta Somaiah, Anthony Conley, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 401–409.
https://doi.org/10.1158/1078-0432.CCR-22-2509
Published: 17 January 2023
View article titled, Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)
Open the PDF for Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102) in another window
Includes: Supplementary data
Journal Articles

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J. Haley, Anna Maria V. Storniolo, Mridula P. Reddy, Scott A. Anderson, Collin T. Zimmerman, Anne P. O'Dea, Hamid R. Mirshahidi, Jordi Rodon Ahnert, Frank J. Brescia, Olwen Hahn, Jane M. Raymond, David D. Biggs, Roisin M. Connolly, Elad Sharon, Larissa A. Korde, Robert J. Gray, Edward Mayerson, Melissa Plets, Charles D. Blanke, Young Kwang Chae, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 271–278.
https://doi.org/10.1158/1078-0432.CCR-21-2182
Published: 19 January 2022
View article titled, A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Open the PDF for A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609) in another window
Includes: Supplementary data
Journal Articles

High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

Mònica Sánchez-Guixé, Cinta Hierro, José Jiménez, Cristina Viaplana, Guillermo Villacampa, Erika Monelli, Fara Brasó-Maristany, Zighereda Ogbah, Mireia Parés, Marta Guzmán, Judit Grueso, Olga Rodríguez, Mafalda Oliveira, Analía Azaro, Elena Garralda, Josep Tabernero, Oriol Casanovas, Maurizio Scaltriti, Aleix Prat, Rodrigo Dienstmann, Paolo Nuciforo, Cristina Saura, Mariona Graupera, Ana Vivancos, Jordi Rodon, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 137–149.
https://doi.org/10.1158/1078-0432.CCR-21-1810
Published: 05 January 2022
View article titled, High <em>FGFR1–4</em> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Open the PDF for High <em>FGFR1–4</em> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Javier Garcia-Corbacho, Valentina Boni, Mark Stroh, Alison L. Hannah, Song Wang, Henry Castro, Alexander Spira
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (16): 4521–4530.
https://doi.org/10.1158/1078-0432.CCR-21-0194
Published: 15 August 2021
View article titled, Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Open the PDF for Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies

Aparna Hegde, Priyamvada Jayaprakash, Coline A. Couillault, Sarina Piha-Paul, Daniel Karp, Jordi Rodon, Shubham Pant, Siqing Fu, Ecaterina E. Dumbrava, Timothy A. Yap, Vivek Subbiah, Priya Bhosale, Cristian Coarfa, Jack P. Higgins, Eric T. Williams, Thomas F. Wilson, JoAnn Lim, Funda Meric-Bernstam, Elizabeth Sumner, Hira Zain, Di Nguyen, Ly M. Nguyen, Kimal Rajapakshe, Michael A. Curran, David S. Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3050–3060.
https://doi.org/10.1158/1078-0432.CCR-20-4118
Published: 01 June 2021
View article titled, A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Open the PDF for A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma

Benjamin M. Ellingson, Jingwen Yao, Catalina Raymond, David A. Nathanson, Ararat Chakhoyan, Jeremy Simpson, James S. Garner, Alan G. Olivero, Lars U. Mueller, Jordi Rodon, Elizabeth Gerstner, Timothy F. Cloughesy, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3135–3144.
https://doi.org/10.1158/1078-0432.CCR-19-3817
Published: 01 July 2020
View article titled, Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma
Open the PDF for Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma in another window
Includes: Supplementary data
Journal Articles

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, Cinta Hierro, Maria Ochoa de Olza, Cristina Viaplana, Analia Azaro, Maria Vieito, Irene Braña, Gemma Mur, Javier Ros, Jose Mateos, Guillermo Villacampa, Roger Berché, Mafalda Oliveira, Maria Alsina, Elena Elez, Ana Oaknin, Eva Muñoz-Couselo, Joan Carles, Enriqueta Felip, Jordi Rodón, Josep Tabernero, Rodrigo Dienstmann, Raquel Perez-Lopez, Elena Garralda
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (8): 1846–1855.
https://doi.org/10.1158/1078-0432.CCR-19-2226
Published: 15 April 2020
View article titled, Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Open the PDF for Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

Patrick Y. Wen, Timothy F. Cloughesy, Alan G. Olivero, Kari M. Morrissey, Timothy R. Wilson, Xuyang Lu, Lars U. Mueller, Alexandre F. Coimbra, Benjamin M. Ellingson, Elizabeth Gerstner, Eudocia Q. Lee, Jordi Rodon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1820–1828.
https://doi.org/10.1158/1078-0432.CCR-19-2808
Published: 15 April 2020
View article titled, First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma
Open the PDF for First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma in another window
Journal Articles

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

Funda Meric-Bernstam, Amber M. Johnson, Ecaterina E. Ileana Dumbrava, Kanwal Raghav, Kavitha Balaji, Michelle Bhatt, Rashmi K. Murthy, Jordi Rodon, Sarina A. Piha-Paul
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2033–2041.
https://doi.org/10.1158/1078-0432.CCR-18-2275
Published: 01 April 2019
View article titled, Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Open the PDF for Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Precision Oncology Decision Support: Current Approaches and Strategies for the Future

Katherine C. Kurnit, Ecaterina E. Ileana Dumbrava, Beate Litzenburger, Yekaterina B. Khotskaya, Amber M. Johnson, Timothy A. Yap, Jordi Rodon, Jia Zeng, Md Abu Shufean, Ann M. Bailey, Nora S. Sánchez, Vijaykumar Holla, John Mendelsohn, Kenna Mills Shaw, Elmer V. Bernstam, Gordon B. Mills, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2719–2731.
https://doi.org/10.1158/1078-0432.CCR-17-2494
Published: 14 June 2018
View article titled, Precision Oncology Decision Support: Current Approaches and Strategies for the Future
Open the PDF for Precision Oncology Decision Support: Current Approaches and Strategies for the Future in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

Khaldoun Almhanna, Thea Kalebic, Cristina Cruz, Jason E. Faris, David P. Ryan, JungAh Jung, Tim Wyant, Adedigbo A. Fasanmade, Wells Messersmith, Jordi Rodon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (20): 5049–5057.
https://doi.org/10.1158/1078-0432.CCR-15-2474
Published: 13 October 2016
View article titled, Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies
Open the PDF for Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies in another window
Journal Articles

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

Oriol Arqués, Irene Chicote, Isabel Puig, Stephan P. Tenbaum, Guillem Argilés, Rodrigo Dienstmann, Natalia Fernández, Ginevra Caratù, Judit Matito, Daniel Silberschmidt, Jordi Rodon, Stefania Landolfi, Aleix Prat, Eloy Espín, Ramón Charco, Paolo Nuciforo, Ana Vivancos, Wenlin Shao, Josep Tabernero, Héctor G. Palmer
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 644–656.
https://doi.org/10.1158/1078-0432.CCR-14-3081
Published: 31 January 2016
View article titled, Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
Open the PDF for Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma

Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Siddha N. Kasar, Joanne Lager, Jason Jiang, Coumaran Egile, Farrukh T. Awan
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3160–3169.
https://doi.org/10.1158/1078-0432.CCR-14-3262
Published: 14 July 2015
View article titled, Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Open the PDF for Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma

Yaping Shou, Douglas M. Robinson, Dereck D. Amakye, Kristine L. Rose, Yoon-Jae Cho, Keith L. Ligon, Thad Sharp, Asifa S. Haider, Raj Bandaru, Yuichi Ando, Birgit Geoerger, François Doz, David M. Ashley, Darren R. Hargrave, Michela Casanova, Hussein A. Tawbi, Jordi Rodon, Anne L. Thomas, Alain C. Mita, Tobey J. MacDonald, Mark W. Kieran
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (3): 585–593.
https://doi.org/10.1158/1078-0432.CCR-13-1711
Published: 01 February 2015
View article titled, A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma
Open the PDF for A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma in another window
Includes: Supplementary data